Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/AKT/mammalian target of rapamycin (mTOR) in m...

Full description

Bibliographic Details
Main Authors: Minjeong Yeon, Youngmi Kim, Hyun Suk Jung, Dooil Jeoung
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
anti-cancer drug resistance
HDACs
immune checkpoint
MAPK
melanoma
Online Access:https://www.frontiersin.org/article/10.3389/fcell.2020.00486/full

Internet

https://www.frontiersin.org/article/10.3389/fcell.2020.00486/full

Similar Items